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A B S T R A C T
ABCG2 is one of a trio of human ATP binding cassette transporters that have the ability to bind and transport a
diverse array of chemical substrates out of cells. This so-called “multidrug” transport has numerous physiological
consequences including effects on how drugs are absorbed into and eliminated from the body. Understanding
how ABCG2 is able to interact with multiple drug substrates remains an important goal in transporter biology.
Most drugs are believed to interact with ABCG2 through the hydrophobic lipid bilayer and experimental systems
for ABCG2 study need to incorporate this. We have exploited styrene maleic acid to solubilise ABCG2 from
HEK293T cells overexpressing the transporter, and confirmed by dynamic light scattering and fluorescence
correlation spectroscopy (FCS) that this results in the extraction of SMA lipid copolymer (SMALP) particles that
are uniform in size and contain a dimer of ABCG2, which is the predominant physiological state. FCS was further
employed to measure the diffusion of a fluorescent ABCG2 substrate (BODIPY-prazosin) in the presence and
absence of SMALP particles of purified ABCG2. Autocorrelation analysis of FCS traces enabled the mathematical
separation of free BODIPY-prazosin from drug bound to ABCG2 and allowed us to show that combining SMALP
extraction with FCS can be used to study specific drug: transporter interactions.
1. Introduction
The ATP binding cassette (ABC) family of membrane transporter
proteins couple the hydrolysis of ATP at intracellular nucleotide
binding domains (NBDs) to the binding and transport of substrates
across the membrane. They have a phenomenally diverse array of
physiological roles including nutrient uptake in bacteria, hormone
transport in plants, and bile salt and antigenic peptide transport in
animals [1]. Several family members are capable of exporting a wide
range of chemically diverse compounds from the cell. This unusual
polyspecificity underpins roles in cell, tissue and organ level defence
[2], but in disease states these polyspecific transporters can underlie the
emergence of a treatment refractory state. Such multidrug resistance
(MDR) to chemotherapy drugs can be a contributory factor to poor
prognosis in cancer [3,4]. Three human MDR-type ABC transporters (P-
glycoprotein (ABCB1), multidrug resistance associated protein-1
(ABCC1/MRP1) and breast cancer resistance protein (ABCG2/BCRP))
have been the subject of intensive investigation both to understand
their contribution to cancer MDR and to understand the protein bio-
chemical mechanisms of multidrug recognition and export [5–7].
ABCG2 has specifically been implicated in conferring a cytopro-
tective role in many types of stem cells under conditions of cellular
stress (e.g. hypoxia [8,9]), and it also appears to be involved in the
cellular stress response in autophagy [10]. ABCG2 overexpression has
been linked to poor prognosis in several different haematological ma-
lignancies [11–13], and altered function of ABCG2 due to inherited
polymorphisms is a major risk factor for hyperuricaemia [14–16].
This plethora of physiological roles indicates that ABCG2's substrate
repertoire is diverse. To date, using transport assay screens [17,18],
ABCG2 has been demonstrated to be capable of transporting camp-
tothecins, polyglutamates, statins, anthracyclines and nucleoside ana-
logues amongst others. A similarly wide range of small molecules ap-
pear capable of inhibiting ABCG2 such as tyrosine kinase inhibitors,
immunosuppressants, HIV protease inhibitors and calcium channel
blockers [14,19]. These lists, which include scores of pharmaceutically
useful drugs, implicate ABCG2 as a major contributor to drug uptake
and elimination. Understanding the molecular basis of ABCG2's com-
plex pharmacology is therefore paramount. Early studies demonstrated
that ABCG2 has multiple, pharmacologically distinct sites that are al-
losterically linked to each other, and to the NBDs [20,21]. Recent cryo-
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electron microscopy structural data have led to the identification of
cavities within the transporter at which substrates and inhibitors can
interact [22–24] providing a framework for understanding structure
activity relationships for existing and novel ABCG2 substrates and in-
hibitors [25–27].
Quantitative determination of the binding of substrates and in-
hibitors to ABCG2 will complement structural, theoretical and medic-
inal chemical approaches to better describe ABCG2 and will result in a
molecular understanding of its roles in physiology and pathology. As
the majority of ABCG2 transport substrates are hydrophobic and are
expected to interact via the lipid milieu it is essential that any system
for determining pharmacology includes surrounding lipids. This limits
studies using detergent solubilised protein as this would remove all but
the most tightly associated lipids. Styrene maleic acid (SMA) has
emerged as an adjunct to existing methods of membrane protein ex-
traction [28,29]. It has been demonstrated to extract a huge array of
target membrane proteins from both prokaryotes and eukaryotes into a
near native lipid environment with a lipid shell whose composition
reflects that of the original membranes [28,30].
Herein, we describe a solution-based method using fluorescence
correlation spectroscopy (FCS) to determine the binding of substrate to
ABCG2 in a native-like lipid environment. FCS is an optical technique
which analyses the intensity fluctuations generated as a fluorescent
species diffuses though a small, defined confocal volume (~0.2 fL) to
generate information about its concentration, diffusion and brightness
[31,32]. Following styrene maleic acid co-polymer extraction and
purification of ACBG2, we were able to use FCS and photon counting
histogram (PCH) analysis to confirm that the protein retains a pre-
dominantly homodimeric structure in membrane patches. The solubi-
lised and purified protein in SMALP co-polymers is amenable to
quantitative studies of drug interaction using FCS, because concentra-
tions of fluorescent drug molecules in solution and fluorescent drug
bound to ABCG2 can be simultaneously quantified by virtue of their
different diffusion coefficients. The combination of SMALP purification
and FCS analysis will enable future solution-based pharmacology of
ABCG2 and other membrane proteins.
2. Methods
2.1. Molecular biology
To enable protein purification, existing pcDNA3.1(+)zeo vectors
(Invitrogen) encoding N-terminally superfolder GFP-tagged ABCG2,
CD28, CD86 [33] and SNAP-tagged ABCG2 (NCBI Gene 9429) were
modified by the insertion of a start codon and hexahistidine tag, 5′ to
the original start codon of the GFP/SNAP tag. Polyhistidine tagging was
accomplished by annealing phosphorylated single-stranded oligonu-
cleotides with 5′ (CTAG) and 3′ (GATC) extensions that enabled inser-
tion at an existing NheI restriction site. The original methionine start
codon of the GFP/SNAP tags was subsequently modified by primer
based Quikchange site directed mutagenesis to a leucine, and all con-
structs were sequenced across the entire reading frame (Source
Bioscience, Nottingham, UK).
2.2. Cell culture
HEK293T cells (ATCC CRL-3216) were maintained and transfected
by polyethyleneimine as previously described [33–35]. Stable cell lines
were selected in the presence of 200 μg/mL zeocin (ThermoFisher) and
then routinely passaged in the presence of 40 μg/mL zeocin to maintain
transgene expression. High expressing cell lines were established by
growing clones in multiwell plates, labelling His-SNAP-ABCG2 with
0.3 μM SNAP-Cell TMR-Star (New England Biolabs) and imaging using
an ImageXpress Micro XLS high content analysis system (Molecular
Devices) equipped with TRITC excitation/emission filter sets and a
Zeiss 20× long working distance air objective. The obtained images
were manually assessed for relative brightness as an indicator of protein
expression level. Protein expression was further enhanced by the ad-
dition of sodium butyrate (10 mM) to cell cultures 24 h prior to har-
vesting. To facilitate greater cell densities and yields for protein ex-
pression, stably transfected His-SNAP-ABCG2-expressing HEK293T
cells were adapted to suspension culture by agitation at 180 rpm in flat-
bottomed borosilicate vessels with high levels of cell viability (> 95%)
maintained in media (4.5 g.L−1 glucose Dulbecco's modified Eagle
medium; DMEM) supplemented with 10% v/v foetal bovine serum
(FBS). Final densities of ~2 × 106 cells/mL were routinely achieved
with suspension cell culture.
2.3. Mitoxantrone accumulation assay
The function of N-terminally SNAP-tagged ABCG2 was verified by a
previously described assay in which expression of the transporter limits
intracellular accumulation of the fluorescent substrate mitoxantrone
[33]. Briefly, confluent monolayers of HEK293T cells in 96-well plates
(655090, Greiner Bio-One, Stonehouse, UK) were incubated with ve-
hicle (0.1% v/v DMSO), 8 μM mitoxantrone (MX; Sigma-Aldrich, Poole,
UK), or mitoxantrone plus the ABCG2 inhibitor Ko143 (1 μM; Sigma-
Aldrich) for 2 h at 37 °C 5% CO2. Cells were washed twice with ice-cold
PBS, fixed with 4% w/v paraformaldehyde, and cellular fluorescence
measured using a Flexstation (Molecular Devices) with excitation wa-
velength 607 nm and emission 684 nm. The percentage Ko143 in-
hibitable mitoxantrone accumulation was calculated as follows, where
IMX and Ko143 is the vehicle corrected fluorescence intensity of cells
treated with both MX and Ko143, and where IMX is the vehicle corrected
fluorescence intensity of cells treated with MX alone.
= ×I I
I
% 100MX and Ko MX
MX
143
2.4. SMALP extraction and protein purification
Whole cell membranes were obtained from cells using a 2-step
centrifugation protocol. Cell pellets were resuspended at 5–10 pellet
volumes in membrane isolation buffer (MIB; 10 mM Tris, 0.25 M su-
crose, 0.2 mM CaCl2, pH 7.4) supplemented with protease inhibitors
(protease inhibitor cocktail III, Calbiochem). Cells were then disrupted
by nitrogen cavitation (1000 psi, 15 min, 4 °C, Parr Instrument
Company) and cellular debris collected by centrifugation (1500g,
15 min, 4 °C). The supernatant was applied to thin-walled poly-
propylene tubes and ultracentrifuged for 45 min at 100,000g, 4 °C. The
pelleted whole cell membranes were resuspended in MIB (omitting the
CaCl2) by repeated shearing through a 25G needle. Cell membranes
were snap-frozen at −80 °C in aliquots. SMA2000 (Cray Valley) was
prepared as previously described [36]. SMALP solubilisation was per-
formed using membrane pellets centrifuged (100,000g, 20 min, 4 °C)
and resuspended at 100 mg wet membrane weight/mL SMA buffer
(150 mM NaCl, 50 mM Tris, pH 8.0). SMA was added at a final con-
centration of 2.5% w/v and the suspension was incubated at room
temperature (18–22 °C) for 1 h with gentle rotation. The solubilised
protein was obtained via ultracentrifugation (100,000g, 20 min, 4 °C)
and used without further storage.
Solubilised His-tagged protein was mixed with His-select Cobalt
resin (Sigma) at a ratio of 100 μL resin per 1 mL of solubilised protein
with end-over-end mixing overnight at 4 °C. The mixture was then
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poured into a gravity flow column (Bio-Rad) and the flow through
collected. The resin was washed thrice with 5 bed volumes of SMA
buffer and subsequently with SMA buffer supplemented with 50 mM,
200 mM and 2 M imidazole (each additional step comprising three
separate washes of 2 bed volumes). Protein containing fractions were
identified by SDS-PAGE analysis (using BXP-21 antibody (Merck) at
1:500 dilution or anti-His-HRP conjugate (R&D Systems) at 1:1000 di-
lution on western blots where necessary). Protein containing fractions
were pooled, filtered (0.22 μm) to remove particulate contaminants,
and then concentrated in 10 kDa molecular weight cut-off con-
centrators (Sartorius Vivaspin) to a 10% final volume. Imidazole was
removed by back-dilution and concentration in imidazole free SMA
buffer. Protein concentration was determined using densitometric
analysis of SDS-PAGE gels containing a standard curve of bovine serum
albumin alongside fractions of purified ABCG2.
2.5. SNAP-tag labelling
In intact cells, SNAP-tag labelling was achieved by incubating cells
for 30 min at 37 °C in a 5% CO2 atmosphere with 1 μM SNAP-Cell
Oregon Green (all SNAP labels were from New England Biolabs) fol-
lowed by washing thrice with media prior to imaging. Specificity of
SNAP-tag labelling was ensured by controls pre-incubated with 2 μM
SNAP-Cell-Block under identical conditions. For labelling of purified
SNAP-tagged protein, membranes were resuspended at 100 mg wet
weight per mL of SMA buffer and incubated with 0.5 μM SNAP-Surface
AlexaFluor (AF) 647 for 2 h at room temperature, prior to solubilisation
with SMA and purification as described above.
2.6. Confocal microscopy
To confirm expression and membrane localisation of protein con-
structs cells were imaged live using confocal microscopy. Cells were
seeded at 2.5 × 105 cells/well in 35 mm glass bottom dishes (MatTek
Corp) 24 h prior to imaging. Cells were subsequently washed twice with
pre-warmed (37 °C) phenol-red free HBSS (Hank's Balanced Salt
Solution, Sigma-Aldrich) immediately prior to imaging on a LSM710
confocal laser scanning microscope (Carl Zeiss, Jena, Germany), using a
Plan-Apochromat 63×/1.40 Oil Ph3 DIC M27 objective. Images
(1024 × 1024 pixels with 8-bit image depth) were collected using an
argon laser, with excitation wavelength of 488 nm and emission col-
lected either at 500-550 nm (GFP-tagged proteins) or 493-598 nm
(SNAP-AF488 labelled proteins) using a 90 μm pinhole. Gain and offset
settings were adjusted to maintain signal within the linear range of the
detector and were maintained within each experiment.
2.7. DLS
Hydrodynamic measurements were made using a Zetasizer Nano
instrument. SMALPs were diluted 10-fold in SMA buffer, equilibrated to
25 °C, and data then collected for 10s per read with 5–10 reads per
sample. Mean particle hydrodynamic radii and relative component
proportions were calculated from at least three independent prepara-
tions of SMALP solubilised proteins.
2.8. Fluorescence correlation spectroscopy (FCS) measurements
FCS measurements were performed on a Zeiss LSM510NLO
Confocor 3 (Carl Zeiss, Jena, Germany) using a 40× c-Apochromat 1.2
NA water-immersion objective using either argon (488 nm excitation)
or helium‑neon (HeNe) (633 nm excitation) lasers.
The microscope was aligned and calibrated on each experimental
day using rhodamine 6G (for 488 nm-excitation beampaths) or Cy5-
NHS ester (for 633 nm excitation beampaths) as previously described
[33,37,38] to allow calculation of the measurement volume and sub-
sequent sample concentrations and diffusion coefficients. Solutions
containing fluorescently tagged protein or compound were added to the
wells of a Nunc™ Lab-Tek™ 8-well chambered #1.0 cover glass (Ther-
moFisher). The samples were prepared in a final volume of 150-300 μL
depending on the requirement for the experiment. BODIPY-Prazosin
(ThermoFisher) or GFP tagged proteins were excited with 488 nm laser
and emission collected with a 505-550 nm bandpass filter. SNAP Sur-
face Alexa Fluor® 647 labelled samples were excited with 633 nm laser
and emission was collected through a 650 nm longpass filter. In both
cases a pinhole diameter of 1 Airy Unit (70 μm for 488 nm excitation,
90 μm for 633 nm excitation) was used. Fluorescence intensity fluc-
tuations were collected for 3 × 10–100 s as indicated using a laser
power of ~0.3 kW/cm2.
2.9. Data analysis
FCS data were analysed using autocorrelation (AC) or photon
counting histogram (PCH) analysis using Zen 2012 software (Carl Zeiss,
Jena, Germany). Autocorrelation curves for both direct measurement of
SMALP purified ABCG2 and BODIPY-prazosin binding were fitted using
a two-component 3D diffusion model incorporating a pre-exponential
triplet term to account for fluorophore photophysics, with triplet life-
time constrained to<10 μs. For all fits, the structure parameter was
fixed to that measured in the calibration read for the appropriate wa-
velength. For direct measurements of SMALP-purified ABCG2 dwell
times for both components were allowed to vary freely, with compo-
nent one (τD1) constrained to 300-600 μs representing diffusion of
single SMALPs as determined from preliminary experiments. For
BODIPY-prazosin binding experiments, dwell time for component 1
(τD1) was fixed to that of free BODIPY-prazosin as measured directly at
20 nM in solution (40-60 μs), with the second component (τD2) con-
strained to 180-400 μs, as determined from direct measurements of
SMALP-purified ABCG2. For multicomponent fits, concentrations of
each component were calculated from their fractional contributions
towards the total particle number and converted to concentrations
using the calibrated volume size as previously described [37]. Photon
counting histograms were generated from fluorescence fluctuations in
Zen 2012 using a 20 μs bin time, and fitted to a two-component PCH
model, with a first order correction fixed to that determined from PCH
analysis of the rhodamine calibration data.
3. Results and discussion
3.1. Solubilisation of ABCG2 into styrene maleic acid lipid co-polymers
In this study SMA was used to isolate ABCG2 from stably over-
expressing human cell lines. ABCG2 N-terminally tagged with GFP
could be effectively solubilised (essentially 100% of ABCG2 was re-
covered in the soluble fraction) from HEK293T cell membranes by 2.5%
w/v SMA in 1 h at room temperature (Fig. 1A). Parallel solubilisations
with 2 control proteins (CD28-GFP and CD86-GFP), which represent
dimeric and monomeric membrane proteins respectively [33,39,40]
were also completely solubilised by a similar treatment with SMA
(Fig. 1B, C). Particle analysis of SMALPs was performed by dynamic
light scattering and provided evidence of a consistent size (8–10 nm
radius) and narrow distribution for the majority of nanodisc particles
(Table 1 and Supplementary Fig. 1), consistent with data published for
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other membrane systems [41–43]. In each case the remaining ~5% of
particles were considerably larger and anticipated to be SMALP ag-
gregates.
3.2. ABCG2 is dimeric in SMALPs
Determination of ABCG2 function in SMALPs first requires valida-
tion that the protein is in a physiological oligomeric state. Homo-di-
merisation of this transporter is the minimal oligomeric state essential
for function [19,44] and cryo-EM has provided structural confirmation
of the homodimer [22–24]. Fluorescence correlation spectroscopy and
photon counting histogram (PCH) analysis, together with stepwise
photobleaching experiments have also provided evidence of ABCG2
oligomers in the plasma membrane of living cells [33]. Here, FCS and
PCH were used to determine the diffusion characteristics and oligo-
meric state of SMALP-purified monomeric and dimeric control proteins
(CD28 and CD86, respectively) and compare these to ABCG2 in
SMALPs.
Fluorescence fluctuation traces for SMALP-encapsulated ABCG2
were initially obtained (Fig. 2A) and autocorrelation analysis per-
formed (Fig. 2B). The autocorrelation curve was best fit using a 2-
component curve as indicated by analysis of the fitting residual
(Fig. 2B, lower panel). The first of these components had a dwell time
(τD1) of approximately 180 μs, which corresponded to a diffusion
coefficient (D) of 31.2 ± 4.3 μm2s−1 (Fig. 3A, Table 2). An additional,
slower component with D of 1.8 ± 0.5 μm2s−1 was also detected in
these experiments, but this represented only ~11% of the total sample.
Consistent with the DLS data above, this most likely represents ag-
gregated SMALPs. Using this diffusion coefficient in the Stokes-Einstein
equation, with the proviso that SMALP particles are not spherical, gives
an estimate of hydrodynamic radius of 7–9 nm, consistent with the DLS
data. Similar diffusion coefficients for unit SMALP encapsulated CD86
and CD28 were obtained, and confirm the relatively uniform size of
extraction by SMA polymer (Fig. 3A; Table 2).
PCH analysis of ABCG2 fluctuations was also best fit with two
components (Fig. 2C), with a less bright component constituting 94.6%
of the total particles, with 5.4% of the particles exhibiting a 7.8-fold
higher molecular brightness (Table 3). This is consistent with the au-
tocorrelation and DLS data and suggests that the brighter component
represents aggregated SMALPs and the majority component re-
presenting individual SMALP particles. Photon counting histogram
(PCH) analysis of monomeric (CD86) and dimeric (CD28) standards
were also compared to investigate the stoichiometry of ABCG2 protein
in the SMALP particles (Fig. 3B). As with ABCG2, both samples showed
a predominant (> 90%) bright component with small amount (< 7%)
of 8–10-fold brighter species.
Analysis of component 1 of the PCH analysis for all three SMALP
species (Fig. 3B) indicated that the molecular brightness (ε, counts per
molecule per second) of CD86 (monomeric control protein [33,40]) was
27,074 ± 6975 cpms−1 (n = 3) whilst that for CD28 (dimeric control)
was 2.2-fold higher (60,030 ± 7406 cpms−1, n = 3).This confirmed
that PCH analysis of SMALP encapsulated proteins could correctly de-
termine the relative stoichiometry of monomeric and dimeric states
(Table 3). In comparison to CD28 and CD86, the molecular brightness
for the equivalent component of the ABCG2 PCH analysis was
51,199 ± 2135 cpms−1 (n = 3), which was 1.9-fold that of the
monomeric CD86, and not significantly different from that of CD28
(p = 0.25), demonstrating that ABCG2 is essentially dimeric within the
SMALP particle (Fig. 3B). The consistency of SMALP particle sizes ex-
cludes the possibility that variations in overall SMALP size and/or
heterogeneity could contribute to differences seen in molecular
Fig. 1. Solubilisation of membrane proteins by styrene maleic
acid. GFP-tagged proteins were solubilised from membranes
(100 mg wet weight mL−1) with 2.5% w/v SMA for 1 h at
room temperature prior to ultracentrifugation to separate
soluble from insoluble fractions. Insoluble material was re-
suspended back into the original volume in SMA buffer sup-
plemented with 2% w/v SDS. Blots shown are representative
of n = 3 independent experiments.
Table 1
Particle size analysis of SMALP encapsulated ABCG2.
Protein Hydrodynamic radius (nm) Unit particle frequency (%)
ABCG2 9.8 ± 0.5 96.9 ± 2.5
CD28 9.5 ± 1.0 95.6 ± 3.9
CD86 7.5 ± 1.6 96.5 ± 3.3
Samples of solubilised membrane material from cell lines expressing the given
proteins were analysed by DLS. The size distribution showed the predominant
particle sizes in each case (n = 3, mean ± SD).
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brightness measurements. Confirmation of ABCG2's (and CD28's) di-
meric status in SMALPs adds to accumulating evidence that SMA ex-
tracts membrane proteins of diverse folds and functions into particles
containing the native oligomer. For example, AcrB was extracted as a
trimer [45] and KcsA has been extracted as a tetramer [46].
3.3. N-terminal tagging of ABCG2 with a SNAP-tag does not impair
localisation or function
Having confirmed that SMALP extraction preserved the dimeric
form of ABCG2 as detected in live cells, we then determined whether
FCS could be applied to quantify ABCG2:substrate interactions. Using
the GFP-ABCG2 construct would limit this approach to fluorescent
drugs whose spectra do not overlap with GFP. Construction of an
ABCG2 fusion with a SNAP-tag protein, for which a range of different
SNAP-ligands is available, would allow discrimination between
ABCG2 and a wider range of fluorescent substrates. An ABCG2 variant
with a His6-SNAP-tag at the N-terminus was expressed stably in
mammalian HEK293T cells (Fig. 4A, left panel). Labelling of cells
expressing His6-SNAP-ABCG2 with cell-permeable SNAP-Cell Oregon
Green confirmed a predominant membrane localisation of the pro-
tein; specific labelling for the tagged ABCG2 variant was completely
blocked by pre-incubation with non-fluorescent SNAP-Cell Block re-
agent (benzyl guanine; Fig. 4A middle and right panels). The function
of this ABCG2 construct was validated with a drug transport assay
[33], in which the cellular export of the fluorescent drug substrate
mitoxantrone [47] was determined in the presence or absence of the
inhibitor Ko143 [48]. Although Ko143 has some inhibitory activity
towards ABCB1 we employed it at 1 μM, a concentration at which it is
effectively ABCG2-specific [49]. Ko143 inhibited ~80% of mitoxan-
trone transport in His6-SNAP-ABCG2 expressing cells, with no sig-
nificant transport in untransfected cells (Fig. 4B). This function was
comparable to other N-terminally labelled ABCG2 constructs which
have previously been studied [34,50–52] indicating that the SNAP tag
does not impact negatively on either membrane trafficking or trans-
port function of ABCG2.
His6-SNAP-ABCG2 was also labelled by SNAP fluorophores in
membrane preparations (Fig. 4C) and this was not disrupted by the
addition of membrane solubilising detergents (Triton X-100). Fol-
lowing labelling of membranes, we employed SMA to solubilise His6-
SNAP-ABCG2 under identical conditions to those described earlier,
and took advantage of the N-terminal hexahistidine tag to purify the
protein using Co2+ affinity chromatography. SMALP-ABCG2 was
concentrated to approximately 2 μM (Fig. 4D, E). Interestingly, and
consistent with other reports (see refs within [28]), we observed that
the affinity of SMA-encapsulated ABCG2 for metal chelated resins was
lower than when the protein was solubilised in non-denaturing de-
tergents. Presumably, some interaction between SMA and the His-tag
results in either an occlusion of the tag or weaker binding to the resin.
We observed that washing the resin in the absence of imidazole re-
moved most contaminating proteins; using 20–50 mM imidazole
washes was then sufficient to then elute the target protein from the
resin. Gel analysis of purified protein showed a small number of
contaminating species so we performed parallel purifications of un-
transfected HEK293T cells. This enabled both ABCG2-enriched and
non-ABCG2 containing SMALPs to be prepared for subsequent FCS
analysis (Fig. 4E).
3.4. Transport substrate binding to ABCG2 demonstrated by FCS
Currently, determination of drug binding to ABCG2 is restricted to
radioligand binding of isotope labelled substrates. Though informative
[20,21] these studies are restricted to the use of isotope labelled dau-
nomycin which is only a substrate for the R482G/A/T mutant versions
of ABCG2 [53]. Development of fluorescence based assays to study
ABCG2 pharmacology would extend our ability to develop structure
activity relationships for this multidrug pump. Purified, SMALP-en-
capsulated ABCG2 was used to determine the potential for pharmaco-
logical investigations of soluble ABCG2 in a membrane environment. In
principle, the binding of a small, fluorescent substrate to ABCG2 should
be accompanied by a significant reduction in its diffusion coefficient, as
determined by the change in mass (~1 kDa to ~250 kDa; estimated
mass of ABCG2 dimer in a SMALP-ed section of membrane, see e.g.
[45]). As with previous FCS studies on purified proteins, this should
yield a sufficient difference in the diffusion coefficient between fast-
moving free ligand and slower-moving bound ligand to enable con-
centrations of free and bound drug to be determined from a single
autocorrelation function [54].
For these experiments, BODIPY-prazosin was used as a fluorescent
transport substrate, as it has previously been shown to be a substrate for
ABCG2 [50]. Initially, we characterised the diffusion of the two in-
dividual components in isolation. Fluorescence fluctuations were col-
lected from solutions of AF647 labelled SNAP-ABCG2-SMALPs and
analysed through autocorrelation analysis as previously described
(Fig. 5A). Autocorrelation analysis revealed a single component with a
diffusion coefficient of D = 26.7 ± 3.0 μm2s−1 (n = 5) which was
Table 2
SMALP diffusion coefficient as calculated by fluorescence correlation spectro-
scopy and subsequent autocorrelation analysis.
Protein Component 1 Component 2
Fraction (%) D (μm2s−1) Fraction (%) D (μm2s−1)
ABCG2 88.5 ± 5.2 31.2 ± 4.3 11.5 ± 5.2 1.8 ± 0.5
CD28 95.7 ± 2.7 32.5 ± 3.6 4.3 ± 2.7 2.8 ± 0.9
CD86 98.7 ± 1.4 37.8 ± 3.0 1.3 ± 1.4 2.1 ± 0.9
FCS data were analysed with a 2-component model as described in the methods
to determine diffusion components of SMALP particles in solution. Values given
represent the mean ± SD for three independent experiments, with multiple
fluctuation reads within each sample.
Table 3
PCH analysis of SMALP encapsulated ABCG2, and monomeric (CD86) and di-
meric (CD28) controls.
Protein Component 1 Component 2
Fraction (%) ε (cpm.s−1) Fraction (%) ε (cpm.s−1)
ABCG2 94.6 ± 1.6 51,999 ± 2135 5.4 ± 1.6 408,163 ± 12,498
CD28 93.8 ± 1.3 60,030 ± 7406 6.2 ± 1.3 465,789 ± 71,770
CD86 93.0 ± 1.5 27,074 ± 6975 7.0 ± 1.5 271,957 ± 47,354
Fluorescence fluctuations were analysed by PCH analysis using a 2-component
model as described in the text. Values given represent the mean ± SD for three
independent experiments.
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similar to that seen for GFP-ABCG2 (Fig. 6A). Fluorescence fluctuations
and subsequent autocorrelation analysis were also obtained for
BODIPY-prazosin (500 nM) in assay buffer (green trace, Fig. 5B). This
yielded a single component autocorrelation curve with a single diffu-
sion component of 453.3 ± 11.9 μm2s−1 (n = 3), 17-fold faster than
that of SNAP-ABCG2-SMALP particles (Fig. 6A).
ABCG2-SMALP (20–30 nM) was subsequently added to BODIPY-
prazosin (500 nM) in assay buffer and incubated for 30 min.
Fluorescence fluctuations were collected, and subsequent autocorrela-
tion analysis revealed a biphasic curve. Restricting the fast component
of this curve to the dwell time of free BODIPY-prazosin in solution (see
Methods) revealed a second, slower diffusing component. This com-
ponent had a diffusion coefficient of 37.0 ± 10.1 μm2s−1 (n = 3,
P = n.s. compared to SNAP-ABCG2 alone) and represented BODIPY-
prazosin bound to SMALP encapsulated ABCG2 (Figs. 5B; 6A).
Whilst these initial experiments clearly indicated binding of a pro-
portion of the BODIPY-prazosin to SMALP particles encapsulating the
SNAP-ABCG2, this binding could be specific (to ABCG2 itself) or non-
specific (to lipid, SMA polymer for instance). Further experiments were
performed to identify the specific component of the binding. In each
case, absolute concentrations of free and bound ligand were determined
following fitting of the autocorrelation curves to a two-component fit,
with diffusion times defined based on those determined for free ligand
and directly labelled SMALP.
Firstly, a comparison was made between the bound levels of ligands
(component 2) in SMALPs containing SNAP-ABCG2 and equivalent
Fig. 4. SNAP-ABCG2 surface expression, activity and purification. SNAP-ABCG2 expressing cells were labelled for 30 min at 37 °C 5% CO2 with 1 μM SNAP-Cell
Oregon Green alone (middle) or after pre-incubation with 2 μM SNAP-Cell ® Block (right panel). After washing cells were imaged using an LSM710 confocal
microscope (Carl Zeiss) with fluorescence images gathered using 488 nm/493-598 nm excitation/emission wavelengths. Scale bar = 20 μm. (B) Corrected mitox-
antrone (MX) fluorescence intensity values were compared in the presence and absence of Ko143 and the function of ABCG2 was determined as % Ko143 inhibitable
MX accumulation. Data are plotted as mean ± SD (n = 4) with statistical significance (****, p < 0.001) compared to parental HEK293T assessed by unpaired t-
test. (C) Labelling of SNAP-ABCG2 in membrane fractions prior to purification. Membranes were incubated with SNAP-Surface AlexaFluor® 647 in the presence (+)
of absence (−) of 0.5% v/v Triton X-100 for the indicated times and fluorescence measured with a fluorimeter. (D) Purification of SNAP-ABCG2 by metal affinity
chromatography, following SMALP solubilisation. Fractions indicate whole cell membranes (M), SMALP-insoluble (I), SMALP-soluble (S), flow through (FT), wash
(W) and elution (E). (E) Purification fractions containing purified SNAP-ABCG2 were concentrated by centrifugation. A preparation of material from cells not
expressing ABCG2 was treated similarly. 10 μL of each of these samples was run on an 8% (w/v) polyacrylamide gel and stained InstantBlue. ABCG2 (identified *)
and some contaminants were revealed.
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Fig. 5. FCS analysis of SMALP-SNAP-ABCG2 and the binding of BODIPY-prazosin. (A) SMALPs were prepared from ABCG2-SNAP expressing cells, labelled with
SNAP-Surface AlexaFluor 647 as described in Methods, and fluorescence fluctuations (upper) were recorded and autocorrelation curves generated. (B) Fluorescence
fluctuations (upper) and subsequent autocorrelation curves (lower) were obtained for BODIPY-prazosin (50 nM) in the absence (green) and presence (blue) of
unlabelled SMALP-ABCG2-SNAP, showing the presence of an additional slower component in the presence of purified ABCG2, representing bound BODIPY-prazosin.
Data are from a single experiment representative of those described in Fig. 6.
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amounts (in terms of protein content) of ‘empty’ SMALPs, i.e. those
extracted from HEK293 cells not expressing ABCG2 (Fig. 4E). Over a
range of protein concentrations, in the presence of 50 nM BODIPY-
prazosin, the levels of bound ligand were significantly higher than those
in empty SMALPs (Fig. 6B). This indicated that a significant proportion
of the bound ligand detected in ABCG2 SMALPs represented specific
binding to the ABCG2 protein.
Further confirmation that the bound component represented spe-
cific binding to ABCG2 was obtained by investigating the effect of un-
labelled prazosin on levels of BODIPY-prazosin binding in ABCG2
containing SMALPs. As demonstrated in Fig. 6C, pre-incubation with
1 μM prazosin caused a significant decrease in the amount of bound
ligand detected in FCS experiments. Determination of the specific
binding and displacement of BODIPY-prazosin to wild type ABCG2
opens up the possibility of explore transport substrate and inhibitor
interactions of this MDR pump.
Numerous studies have shown that there is a complex pharmacology
for ABCG2 [21,55] that is beginning to be understood at the structural
level through cryo-EM observations on the protein [22–24]. De-
termining how mutations (or naturally occurring single nucleotide
polymorphisms) in ABCG2 contribute to altered substrate transport is
easily achieved using flow cytometry [34,56,57] but direct quantifica-
tion of how mutations/SNPs may affect the initial drug binding step can
now be envisaged as possible using SMALPed ABCG2 and FCS. A similar
FCS based approach has also been applied to another of the human
multidrug pumps, ABCB1, and provides further evidence of the ex-
perimental possibilities of FCS studies of transporters in solution [58].
Importantly, given the observed evidence for ABCG2 to impact on drug
pharmacokinetics [14] and the need to quantify how new drugs interact
with ABCG2 [59], this technique – which employs small amounts of
purified protein - may have the potential to address these quantitative
aspects of drug:transporter interaction.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbamem.2020.183218.
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Fig. 6. Quantification of BODIPY-pra-
zosin free and bound components and
determination of specific binding. (A)
Autocorrelation analysis of BODIPY-
prazosin in the presence of SMALP-
ABCG2-SNAP yielded two components
with differing diffusion coefficients:
component C1 (‘free’) and C2
(‘bound’), respectively. Also shown are
the diffusion coefficients for BODIPY-
prazosin alone (green) and SNAP-
Surface Alexa Fluor 647 labelled
SMALP-ABCG2 (red) indicating these
are comparable to the C1 and C2 re-
spectively. Data shown are
mean ± SD of 3 independent pre-
parations, each measured in triplicate.
Data were analysed by ANOVA and
Tukey's multiple comparisons test and
the significant difference between in
diffusion co-efficient of bound
BODIPY-prazosin (C2) compared to
free BODIPY-prazosin (C2) is shown
(**, p < 0.01). (B) BODIPY-prazosin
(50 nM) was incubated with increasing
concentrations of SMALP-ABCG2-
SNAP (blue) or equivalent non-ABCG2-
expressing SMALPs (negative control;
red) for 30 min. Subsequent auto-
correlation of fluorescence fluctuations
allowed the concentrations of bound
ligand (C2) to be determined in each
sample. Data are shown as
mean ± SEM, n = 3 independent
preparations, each performed in tri-
plicate. (C) SMALP-ABCG2-SNAP
(100 nM) was incubated in the pre-
sence (prazosin) or absence (Ctrl) of
1 μM prazosin for 30 min prior to in-
cubation with 50 nM BODIPY-prazosin
for a further 30 min. Concentrations of
bound BODIPY-prazosin were de-
termined from autocorrelation ana-
lysis. Data were assessed for sig-
nificance by unpaired t-test
(** < 0.01) (mean ± SD, n = 3 in-
dependent experiments).
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